GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Theratechnologies Inc (TSX:TH) » Definitions » Gross Profit

Theratechnologies (TSX:TH) Gross Profit : C$78.5 Mil (TTM As of Feb. 2024)


View and export this data going back to 1998. Start your Free Trial

What is Theratechnologies Gross Profit?

Theratechnologies's gross profit for the three months ended in Feb. 2024 was C$14.8 Mil. Theratechnologies's gross profit for the trailing twelve months (TTM) ended in Feb. 2024 was C$78.5 Mil.

Gross Margin % is calculated as gross profit divided by its revenue. Theratechnologies's gross profit for the three months ended in Feb. 2024 was C$14.8 Mil. Theratechnologies's Revenue for the three months ended in Feb. 2024 was C$21.9 Mil. Therefore, Theratechnologies's Gross Margin % for the quarter that ended in Feb. 2024 was 67.48%.

Theratechnologies had a gross margin of 67.48% for the quarter that ended in Feb. 2024 => Durable competitive advantage

During the past 13 years, the highest Gross Margin % of Theratechnologies was 86.61%. The lowest was 58.75%. And the median was 68.92%.


Theratechnologies Gross Profit Historical Data

The historical data trend for Theratechnologies's Gross Profit can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Theratechnologies Gross Profit Chart

Theratechnologies Annual Data
Trend Nov14 Nov15 Nov16 Nov17 Nov18 Nov19 Nov20 Nov21 Nov22 Nov23
Gross Profit
Get a 7-Day Free Trial Premium Member Only Premium Member Only 49.16 51.18 58.52 72.37 85.16

Theratechnologies Quarterly Data
May19 Aug19 Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24
Gross Profit Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 20.47 17.09 21.41 25.20 14.80

Competitive Comparison of Theratechnologies's Gross Profit

For the Biotechnology subindustry, Theratechnologies's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Theratechnologies's Gross Profit Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Theratechnologies's Gross Profit distribution charts can be found below:

* The bar in red indicates where Theratechnologies's Gross Profit falls into.



Theratechnologies Gross Profit Calculation

Gross Profit is the different between the sale prices and the cost of buying or producing the goods.

Theratechnologies's Gross Profit for the fiscal year that ended in Nov. 2023 is calculated as

Gross Profit (A: Nov. 2023 )=Revenue - Cost of Goods Sold
=112.074 - 26.914
=85.2

Theratechnologies's Gross Profit for the quarter that ended in Feb. 2024 is calculated as

Gross Profit (Q: Feb. 2024 )=Revenue - Cost of Goods Sold
=21.933 - 7.133
=14.8

Gross Profit for the trailing twelve months (TTM) ended in Feb. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was C$78.5 Mil.

Gross Profit is the numerator in the calculation of Gross Margin.

Theratechnologies's Gross Margin % for the quarter that ended in Feb. 2024 is calculated as

Gross Margin % (Q: Feb. 2024 )=Gross Profit (Q: Feb. 2024 ) / Revenue (Q: Feb. 2024 )
=(Revenue - Cost of Goods Sold) / Revenue
=14.8 / 21.933
=67.48 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


Theratechnologies  (TSX:TH) Gross Profit Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Theratechnologies had a gross margin of 67.48% for the quarter that ended in Feb. 2024 => Durable competitive advantage


Theratechnologies Gross Profit Related Terms

Thank you for viewing the detailed overview of Theratechnologies's Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.


Theratechnologies (TSX:TH) Business Description

Traded in Other Exchanges
Address
2015, rue Peel, 11e etage, Montreal, QC, CAN, H3A 1T8
Theratechnologies Inc is a specialty pharmaceutical company that addresses the unmet medical needs of HIV patients. It mainly operates in Canada and the United States. The company has two approved products, EGRIFTA marketed in Canada and the United States, and Trogarzo approved for commercialization in the United States.
Executives
Joseph Arena Director
Philippe Dubuc Senior Officer
Gérald A. Lacoste Director
Paul Lévesque Senior Officer
Andrew Molson Director
Dawn Svoronos Director
John Leasure Senior Officer